Cargando…
Systemic vasculitis associated with vemurafenib treatment: Case report and literature review
RATIONALE: Vemurafenib, an inhibitor of mutated B-rapidly accelerated fibrosarcoma, is frequently used in the treatment of melanoma and Erdheim–Chester disease (ECD) patients. Inflammatory adverse effects have been increasingly reported after vemurafenib treatment. PATIENT CONCERNS AND DIAGNOSE: We...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120889/ https://www.ncbi.nlm.nih.gov/pubmed/27861332 http://dx.doi.org/10.1097/MD.0000000000004988 |
_version_ | 1782469317195988992 |
---|---|
author | Mirouse, Adrien Savey, Léa Domont, Fanny Comarmond, Cloé Barete, Stéphane Plaisier, Emmanuelle Rouvier, Philippe Cacoub, Patrice Saadoun, David |
author_facet | Mirouse, Adrien Savey, Léa Domont, Fanny Comarmond, Cloé Barete, Stéphane Plaisier, Emmanuelle Rouvier, Philippe Cacoub, Patrice Saadoun, David |
author_sort | Mirouse, Adrien |
collection | PubMed |
description | RATIONALE: Vemurafenib, an inhibitor of mutated B-rapidly accelerated fibrosarcoma, is frequently used in the treatment of melanoma and Erdheim–Chester disease (ECD) patients. Inflammatory adverse effects have been increasingly reported after vemurafenib treatment. PATIENT CONCERNS AND DIAGNOSE: We report 6 cases of vemurafenib-associated vasculitis, of whom a personal case of a 75-year-old man with history of ECD who developed purpura and rapidly progressive pauci-immune glomerulonephritis during treatment with vemurafenib. INTERVENTION: In the 5 others cases from the literature, all patients presented skin vasculitis, and with joint involvement in 60% of them. Vemurafenib treatment was stopped (n = 3), continued at reduced doses (n = 1), or continued at the same dose (n = 2). OUTCOMES: Three patients (50%) received corticosteroids combined with cyclophosphamide (n = 1), and all achieved remission of vasculitis. One patient experienced vasculitis relapse after vemurafenib therapy was restarted. LESSONS: Systemic vasculitis is a rare vemurafenib-associated adverse event that may be life-threatening. |
format | Online Article Text |
id | pubmed-5120889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-51208892016-11-28 Systemic vasculitis associated with vemurafenib treatment: Case report and literature review Mirouse, Adrien Savey, Léa Domont, Fanny Comarmond, Cloé Barete, Stéphane Plaisier, Emmanuelle Rouvier, Philippe Cacoub, Patrice Saadoun, David Medicine (Baltimore) 3600 RATIONALE: Vemurafenib, an inhibitor of mutated B-rapidly accelerated fibrosarcoma, is frequently used in the treatment of melanoma and Erdheim–Chester disease (ECD) patients. Inflammatory adverse effects have been increasingly reported after vemurafenib treatment. PATIENT CONCERNS AND DIAGNOSE: We report 6 cases of vemurafenib-associated vasculitis, of whom a personal case of a 75-year-old man with history of ECD who developed purpura and rapidly progressive pauci-immune glomerulonephritis during treatment with vemurafenib. INTERVENTION: In the 5 others cases from the literature, all patients presented skin vasculitis, and with joint involvement in 60% of them. Vemurafenib treatment was stopped (n = 3), continued at reduced doses (n = 1), or continued at the same dose (n = 2). OUTCOMES: Three patients (50%) received corticosteroids combined with cyclophosphamide (n = 1), and all achieved remission of vasculitis. One patient experienced vasculitis relapse after vemurafenib therapy was restarted. LESSONS: Systemic vasculitis is a rare vemurafenib-associated adverse event that may be life-threatening. Wolters Kluwer Health 2016-11-18 /pmc/articles/PMC5120889/ /pubmed/27861332 http://dx.doi.org/10.1097/MD.0000000000004988 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | 3600 Mirouse, Adrien Savey, Léa Domont, Fanny Comarmond, Cloé Barete, Stéphane Plaisier, Emmanuelle Rouvier, Philippe Cacoub, Patrice Saadoun, David Systemic vasculitis associated with vemurafenib treatment: Case report and literature review |
title | Systemic vasculitis associated with vemurafenib treatment: Case report and literature review |
title_full | Systemic vasculitis associated with vemurafenib treatment: Case report and literature review |
title_fullStr | Systemic vasculitis associated with vemurafenib treatment: Case report and literature review |
title_full_unstemmed | Systemic vasculitis associated with vemurafenib treatment: Case report and literature review |
title_short | Systemic vasculitis associated with vemurafenib treatment: Case report and literature review |
title_sort | systemic vasculitis associated with vemurafenib treatment: case report and literature review |
topic | 3600 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120889/ https://www.ncbi.nlm.nih.gov/pubmed/27861332 http://dx.doi.org/10.1097/MD.0000000000004988 |
work_keys_str_mv | AT mirouseadrien systemicvasculitisassociatedwithvemurafenibtreatmentcasereportandliteraturereview AT saveylea systemicvasculitisassociatedwithvemurafenibtreatmentcasereportandliteraturereview AT domontfanny systemicvasculitisassociatedwithvemurafenibtreatmentcasereportandliteraturereview AT comarmondcloe systemicvasculitisassociatedwithvemurafenibtreatmentcasereportandliteraturereview AT baretestephane systemicvasculitisassociatedwithvemurafenibtreatmentcasereportandliteraturereview AT plaisieremmanuelle systemicvasculitisassociatedwithvemurafenibtreatmentcasereportandliteraturereview AT rouvierphilippe systemicvasculitisassociatedwithvemurafenibtreatmentcasereportandliteraturereview AT cacoubpatrice systemicvasculitisassociatedwithvemurafenibtreatmentcasereportandliteraturereview AT saadoundavid systemicvasculitisassociatedwithvemurafenibtreatmentcasereportandliteraturereview |